Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
RP-12146 by Rhizen Pharmaceuticals for Breast Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Gastric Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Small-Cell Lung Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...
RP-12146 by Rhizen Pharmaceuticals for Solid Tumor: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
RP-12146 by Rhizen Pharmaceuticals for Fallopian Tube Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
RP-12146 by Rhizen Pharmaceuticals for Peritoneal Cancer: Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...
RP-12146 by Rhizen Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...